Why is Fosun Pharma privatizing Henlius at this time? | Jianzhi Research

The suspension of Henlius stocks has finally been resolved, consistent with previous market rumors: Fosun Pharma will privatize Henlius for delisting, with a privatization valuation of approximately RMB 12.4 billion. Fosun Pharma's bid for each share of Henlius is HKD 24.60, a premium of 30.6% over its pre-suspension closing price. Based on last year's net profit of CNY 546 million for Henlius, this privatization has a PE ratio of approximately 23 times. The total transaction is HKD 5.4 billion, which will use no more than HKD 3.7 billion in acquisition loans. Henlius has a total share capital of 543.5 million shares, including 163.4 million H shares and 380.1 million non-listed shares. The tenderer in this case is Fosun.

wallstreetcnJun 25 03:26 ET

Silence Therapeutics To Receive $2M Research Milestone Payment From Hansoh Pharma, Following The Achievement Of A Second Undisclosed Milestone Related To The First Target Under The Collaboration

BenzingaJun 24 08:35 ET

WuXi AppTec Goes Ex Dividend Tomorrow

Seeking AlphaJun 17 13:24 ET

The total relief rate of Xidacilone race reaches 94%, and sales growth is expected.

On June 4th, Genscript Bio (1548.HK, referred to as "Genscript") announced that its subsidiary, Legend Biotech (LEGN.O), released the results of Phase 2 CARTITUDE-2 (Siltuximab) Cohort D study for the treatment of multiple myeloma patients for the first time at the ASCO Annual Meeting.

wallstreetcnJun 4 22:13 ET

Summit Therapeutics Falls Almost 20% as it Returns Part of Last Week's 280%+ Rally

Jerry KronenbergJun 4 14:23 ET

Did Kang Fang Bio, which collapsed in the past, turn around with “head to head” with K medicine?

Investing in health requires a strong heart.

wallstreetcnMay 31 03:47 ET